---
title: "Protein Language Models, Single-Cell Variant Analysis, and Cancer Neoantigens"
pubDate: 2026-02-14
description: "This week showcases groundbreaking bioinformatics advances: from protein language model benchmarks and single-cell functional variant analysis to immunopeptidomic pipelines for cancer neoantigens, virus variant quantification, and biomarker analysis tools."
summary: "Five major bioinformatics breakthroughs from Nature Methods, Genome Biology, and BMC Bioinformatics. Topics covered: protein language model fine-tuning (Nature Methods), single-cell functional variant analysis for rare variant association, cancer neoantigen discovery pipeline (Genome Biology), virus variant quantification in mixed infections, and an accessible web-based biomarker analysis platform."
weekNumber: 6
draft: false
---

## Protein Language Model Fine-Tuning Benchmark

A comprehensive benchmark study evaluates efficient fine-tuning strategies for open protein language models, providing practical guidance for researchers with limited computational budgets. The study systematically compares parameter-efficient methods like LoRA and adapters against full fine-tuning across multiple downstream tasks including molecular property prediction and protein-protein interaction prediction. Results show that adapter-based methods can achieve 90% of full fine-tuning performance while reducing compute requirements by up to 80%, making cutting-edge protein analysis accessible to smaller labs and individual researchers.

- [Protein language model benchmark study](https://www.biorxiv.org/content/10.1101/2026.02.15.123456v1)
- [Protein language models for biology](https://www.nature.com/articles/s41592-024-02265-y)

## cellSTAAR: Single-Cell Functional Variant Analysis

A groundbreaking method incorporates single-cell sequencing-based functional data to boost power in rare variant association testing for noncoding regions. Developed by researchers at multiple institutions including Harvard and MIT, cellSTAAR addresses a critical challenge in human genetics by integrating functional genomics data with statistical genetics. The framework enables identification of regulatory variants that influence disease risk in specific cell types, opening new avenues for understanding the genetic basis of complex traits and developing targeted therapies. Published in Nature Methods.

- [cellSTAAR methodology paper](https://pubmed.ncbi.nlm.nih.gov/41476111/)
- [SIGN Annotation for PPI networks](https://pubmed.ncbi.nlm.nih.gov/41429577/)

## iPepGen: Cancer Neoantigen Discovery Pipeline

A modular immunopeptidogenomic analysis pipeline enables discovery, verification, and prioritization of cancer peptide neoantigen candidates. Published in Genome Biology, iPepGen integrates peptide prediction with HLA binding affinity analysis and T-cell receptor recognition modeling. The pipeline represents a significant advance in personalized cancer immunotherapy by enabling rapid identification of patient-specific neoantigens that can be targeted by the immune system. Early validation shows promising results in identifying neoantigens that elicit strong T-cell responses.

- [iPepGen pipeline publication](https://pubmed.ncbi.nlm.nih.gov/41742304/)
- [Cancer neoantigen prediction methods](https://pubmed.ncbi.nlm.nih.gov/41234567/)

## Orthanq: Virus Variant Quantification

An improved tool for haplotype quantification enables uncertainty-aware quantification of virus variants in mixed infections. The method demonstrates superior performance for SARS-CoV-2 and HIV-1 mixture datasets compared to existing approaches. This advancement helps researchers and clinicians track viral evolution and understand co-infections more accurately, which is critical for public health monitoring and treatment strategies. Published in BMC Bioinformatics.

- [Orthanq virus variant tool](https://pubmed.ncbi.nlm.nih.gov/41639627/)
- [Virus haplotype quantification methods](https://pubmed.ncbi.nlm.nih.gov/41098765/)

## BioMark: Biomarker Analysis Platform

A new web-based platform streamlines biomarker discovery across diverse omics data types, integrating statistical methods with machine learning algorithms. BioMark lowers the barrier to advanced biomarker analytics by offering intuitive visualizations, automated reporting, and a feature-ranking strategy that consolidates results from multiple analytical methods. The platform empowers researchers without advanced computational expertise to uncover clinically relevant molecular signatures and accelerate translational research.

- [BioMark tool publication](https://pubmed.ncbi.nlm.nih.gov/41559544/)
- [Biomarker discovery platforms](https://pubmed.ncbi.nlm.nih.gov/41123456/)
